PI3KInhibitorpi3kinhibitor

Tolbutamide

By

Tolbutamide

Product: ARV-771

Identifier : DBSNPE000033
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • C Allele (rs1057910 )

Allele Name : CYP2C9*3
Genotype(s) : (C;C) / (A;C)
Type(s) : Effect Directly Studied
Groups : Non-functional CYP2C9; Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996 Aug;6(4):341-9. [PubMed:8873220 ]

PMID: 22374891

Tolbutamide

By

Tolbutamide

Product: Fenofibrate

Identifier : DBSNPE005890
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 818delA (rs9332131 )

Allele Name : CYP2C9*6
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA: Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001 Dec;11(9):803-8. [PubMed:11740344 ]
  2. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 12554792

Tolbutamide

By

Tolbutamide

Product: Ispinesib

Identifier : DBSNPE005891
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 485C>A (rs72558190 )

Allele Name : CYP2C9*15
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11906293

Tolbutamide

By

Tolbutamide

Product: Pramipexole (dihydrochloride)

Identifier : DBSNPE005892
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 353_362delAGAAATGGAA (rs72558188 )

Allele Name : CYP2C9*25
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11594239

Tolbutamide

By

Tolbutamide

Product: (R)-Baclofen

Identifier : DBSNPE005893
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 374G>T
  • 430C>T

Allele Name : CYP2C9*35
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Ciccacci C, Falconi M, Paolillo N, Oteri F, Forte V, Novelli G, Desideri A, Borgiani P: Characterization of a novel CYP2C9 gene mutation and sdivuctural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet Genomics. 2011 Jun;21(6):344-6. doi: 10.1097/FPC.0b013e328344c340. [PubMed:21451434 ]
  2. Lee MY, Borgiani P, Johansson I, Oteri F, Mkrtchian S, Falconi M, Ingelman-Sundberg M: High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase. Pharmacogenomics J. 2014 Aug;14(4):343-9. doi: 10.1038/tpj.2013.41. Epub 2013 Dec 10. [PubMed:24322786 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11095972

Tolbutamide

By

Tolbutamide

Product: Duvelisib

Identifier : DBSNPE005894
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 430C>T (rs1799853 )

Allele Name : CYP2C9*2
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994 Feb;4(1):39-42. [PubMed:8004131 ]
  2. Crespi CL, Miller VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 1997 Jun;7(3):203-10. [PubMed:9241660 ]
  3. Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K, Echizen H: 5-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood. 2004 Apr 15;103(8):3055-7. Epub 2003 Dec 30. [PubMed:15070684 ]
  4. Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E: The impact of CYP2C9 genetics and oral condivaceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos. 2004 May;32(5):484-9. [PubMed:15100169 ]
  5. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  6. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 25759824

Tolbutamide

By

Tolbutamide

Product: Loratadine

Identifier : DBSNPE005895
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1075A>C (rs1057910 )

Allele Name : CYP2C9*3
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996 Aug;6(4):341-9. [PubMed:8873220 ]
  2. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, sdivuctural characterization, subsdivate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996 Sep 15;333(2):447-58. [PubMed:8809086 ]
  3. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 Feb 27;353(9154):717-9. [PubMed:10073515 ]
  4. Kidd RS, Sdivaughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT: Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999 Feb;9(1):71-80. [PubMed:10208645 ]
  5. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K: CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven subsdivates. Pharmacogenetics. 2000 Mar;10(2):95-104. [PubMed:10761997 ]
  6. Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S, Otsubo K: Genetic polymorphisms and functional characterization of the 5-flanking region of the human CYP2C9 gene: in vidivo and in vivo studies. Clin Pharmacol Ther. 2001 Aug;70(2):175-82. [PubMed:11503012 ]
  7. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  8. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 8521497

Tolbutamide

By

Tolbutamide

Product: Cetirizine

Identifier : DBSNPE005896
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1076T>C (rs56165452 )

Allele Name : CYP2C9*4
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB: Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010 Apr;20(4):277-81. doi: 10.1097/FPC.0b013e3283349e84. [PubMed:20150829 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 8521498

Tolbutamide

By

Tolbutamide

Product: ARN-510

Identifier : DBSNPE005897
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1080C>G (rs28371686 )

Allele Name : CYP2C9*5
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001 Aug;60(2):382-7. [PubMed:11455026 ]
  2. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M, Yasar U: Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther. 2004 Aug;76(2):113-8. [PubMed:15289788 ]
  3. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 19250932

Tolbutamide

By

Tolbutamide

Product: SB1318

Identifier : DBSNPE005898
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 449G>A (rs7900194 )

Allele Name : CYP2C9*8
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  2. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  3. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, Cavallari LH: Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther. 2012 Apr;91(4):660-5. doi: 10.1038/clpt.2011.269. Epub 2012 Feb 29. [PubMed:22378156 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 17704298

Tolbutamide

By

Tolbutamide

Product: AZ3147

Identifier : DBSNPE005899
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1003C>T (rs28371685 )

Allele Name : CYP2C9*11
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Higashi MK, Veensdiva DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 Apr 3;287(13):1690-8. [PubMed:11926893 ]
  2. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  3. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  4. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  5. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 10944516

Tolbutamide

By

Tolbutamide

Product: Teneligliptin

Identifier : DBSNPE005900
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1465C>T (rs9332239 )

Allele Name : CYP2C9*12
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 9824642

Tolbutamide

By

Tolbutamide

Product: CVT-314

Identifier : DBSNPE005901
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 269T>C (rs72558187 )

Allele Name : CYP2C9*13
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D: Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics. 2004 Jul;14(7):465-9. [PubMed:15226678 ]
  2. Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H: Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos. 2005 Jun;33(6):749-53. Epub 2005 Mar 11. [PubMed:15764711 ]
  3. Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H: Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica. 2005 Sep;35(9):853-61. [PubMed:16308280 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 7666790

Tolbutamide

By

Tolbutamide

Product: Naltrexone

Identifier : DBSNPE005902
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 374G>A (rs72558189 )

Allele Name : CYP2C9*14
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 14709329

Tolbutamide

By

Tolbutamide

Product: Y-27633 (dihydrochloride)

Identifier : DBSNPE005903
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 895A>G (rs72558192 )

Allele Name : CYP2C9*16
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 12788809

Tolbutamide

By

Tolbutamide

Product: ABC294641

Identifier : DBSNPE005904
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1075A>C
  • 1190A>C
  • 1425A>T

Allele Name : CYP2C9*18
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11030710

Tolbutamide

By

Tolbutamide

Product: 5-hydroxypyrazine-3-carboxylic acid

Identifier : DBSNPE005905
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 389C>G

Allele Name : CYP2C9*26
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 10636887

Tolbutamide

By

Tolbutamide

Product: NG26

Identifier : DBSNPE005906
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 641A>T

Allele Name : CYP2C9*28
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 15533890

Tolbutamide

By

Tolbutamide

Product: Umeclidinium (bromide)

Identifier : DBSNPE005907
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1429G>A

Allele Name : CYP2C9*30
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 12022867

Tolbutamide

By

Tolbutamide

Product: Paradol

Identifier : DBSNPE005908
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 395G>A (rs200183364 )

Allele Name : CYP2C9*33
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Horio T, Takiuchi S, Kawano Y, Minematsu K, Naritomi H, Tomoike H, Sawada J, Miyata T: Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res. 2008 Aug;31(8):1549-57. doi: 10.1291/hypres.31.1549. [PubMed:18971529 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11226258

Tolbutamide

By

Tolbutamide

Product: Fenofibrate

Identifier : DBSNPE005890
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 818delA (rs9332131 )

Allele Name : CYP2C9*6
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA: Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001 Dec;11(9):803-8. [PubMed:11740344 ]
  2. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 12554792

Tolbutamide

By

Tolbutamide

Product: Ispinesib

Identifier : DBSNPE005891
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 485C>A (rs72558190 )

Allele Name : CYP2C9*15
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11906293

Tolbutamide

By

Tolbutamide

Product: Pramipexole (dihydrochloride)

Identifier : DBSNPE005892
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 353_362delAGAAATGGAA (rs72558188 )

Allele Name : CYP2C9*25
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11594239

Tolbutamide

By

Tolbutamide

Product: (R)-Baclofen

Identifier : DBSNPE005893
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 374G>T
  • 430C>T

Allele Name : CYP2C9*35
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Ciccacci C, Falconi M, Paolillo N, Oteri F, Forte V, Novelli G, Desideri A, Borgiani P: Characterization of a novel CYP2C9 gene mutation and sdivuctural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet Genomics. 2011 Jun;21(6):344-6. doi: 10.1097/FPC.0b013e328344c340. [PubMed:21451434 ]
  2. Lee MY, Borgiani P, Johansson I, Oteri F, Mkrtchian S, Falconi M, Ingelman-Sundberg M: High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase. Pharmacogenomics J. 2014 Aug;14(4):343-9. doi: 10.1038/tpj.2013.41. Epub 2013 Dec 10. [PubMed:24322786 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11095972

Tolbutamide

By

Tolbutamide

Product: Duvelisib

Identifier : DBSNPE005894
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 430C>T (rs1799853 )

Allele Name : CYP2C9*2
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994 Feb;4(1):39-42. [PubMed:8004131 ]
  2. Crespi CL, Miller VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 1997 Jun;7(3):203-10. [PubMed:9241660 ]
  3. Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K, Echizen H: 5-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood. 2004 Apr 15;103(8):3055-7. Epub 2003 Dec 30. [PubMed:15070684 ]
  4. Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E: The impact of CYP2C9 genetics and oral condivaceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos. 2004 May;32(5):484-9. [PubMed:15100169 ]
  5. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  6. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 25759824

Tolbutamide

By

Tolbutamide

Product: Loratadine

Identifier : DBSNPE005895
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1075A>C (rs1057910 )

Allele Name : CYP2C9*3
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996 Aug;6(4):341-9. [PubMed:8873220 ]
  2. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, sdivuctural characterization, subsdivate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996 Sep 15;333(2):447-58. [PubMed:8809086 ]
  3. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 Feb 27;353(9154):717-9. [PubMed:10073515 ]
  4. Kidd RS, Sdivaughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT: Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999 Feb;9(1):71-80. [PubMed:10208645 ]
  5. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K: CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven subsdivates. Pharmacogenetics. 2000 Mar;10(2):95-104. [PubMed:10761997 ]
  6. Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S, Otsubo K: Genetic polymorphisms and functional characterization of the 5-flanking region of the human CYP2C9 gene: in vidivo and in vivo studies. Clin Pharmacol Ther. 2001 Aug;70(2):175-82. [PubMed:11503012 ]
  7. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  8. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 8521497

Tolbutamide

By

Tolbutamide

Product: Cetirizine

Identifier : DBSNPE005896
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1076T>C (rs56165452 )

Allele Name : CYP2C9*4
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB: Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010 Apr;20(4):277-81. doi: 10.1097/FPC.0b013e3283349e84. [PubMed:20150829 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 8521498

Tolbutamide

By

Tolbutamide

Product: ARN-510

Identifier : DBSNPE005897
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1080C>G (rs28371686 )

Allele Name : CYP2C9*5
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001 Aug;60(2):382-7. [PubMed:11455026 ]
  2. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M, Yasar U: Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther. 2004 Aug;76(2):113-8. [PubMed:15289788 ]
  3. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 19250932

Tolbutamide

By

Tolbutamide

Product: SB1318

Identifier : DBSNPE005898
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 449G>A (rs7900194 )

Allele Name : CYP2C9*8
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  2. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  3. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, Cavallari LH: Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther. 2012 Apr;91(4):660-5. doi: 10.1038/clpt.2011.269. Epub 2012 Feb 29. [PubMed:22378156 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 17704298

Tolbutamide

By

Tolbutamide

Product: AZ3147

Identifier : DBSNPE005899
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1003C>T (rs28371685 )

Allele Name : CYP2C9*11
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Higashi MK, Veensdiva DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 Apr 3;287(13):1690-8. [PubMed:11926893 ]
  2. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  3. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  4. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  5. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 10944516

Tolbutamide

By

Tolbutamide

Product: Teneligliptin

Identifier : DBSNPE005900
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1465C>T (rs9332239 )

Allele Name : CYP2C9*12
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 9824642

Tolbutamide

By

Tolbutamide

Product: CVT-314

Identifier : DBSNPE005901
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 269T>C (rs72558187 )

Allele Name : CYP2C9*13
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D: Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics. 2004 Jul;14(7):465-9. [PubMed:15226678 ]
  2. Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H: Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos. 2005 Jun;33(6):749-53. Epub 2005 Mar 11. [PubMed:15764711 ]
  3. Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H: Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica. 2005 Sep;35(9):853-61. [PubMed:16308280 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 7666790

Tolbutamide

By

Tolbutamide

Product: Naltrexone

Identifier : DBSNPE005902
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 374G>A (rs72558189 )

Allele Name : CYP2C9*14
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 14709329

Tolbutamide

By

Tolbutamide

Product: Y-27633 (dihydrochloride)

Identifier : DBSNPE005903
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 895A>G (rs72558192 )

Allele Name : CYP2C9*16
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 12788809

Tolbutamide

By

Tolbutamide

Product: ABC294641

Identifier : DBSNPE005904
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1075A>C
  • 1190A>C
  • 1425A>T

Allele Name : CYP2C9*18
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11030710

Tolbutamide

By

Tolbutamide

Product: 5-hydroxypyrazine-3-carboxylic acid

Identifier : DBSNPE005905
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 389C>G

Allele Name : CYP2C9*26
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 10636887

Tolbutamide

By

Tolbutamide

Product: NG26

Identifier : DBSNPE005906
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 641A>T

Allele Name : CYP2C9*28
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 15533890

Tolbutamide

By

Tolbutamide

Product: Umeclidinium (bromide)

Identifier : DBSNPE005907
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1429G>A

Allele Name : CYP2C9*30
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 12022867

Tolbutamide

By

Tolbutamide

Product: Paradol

Identifier : DBSNPE005908
Drug : DB01124 (Tolbutamide)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 395G>A (rs200183364 )

Allele Name : CYP2C9*33
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Horio T, Takiuchi S, Kawano Y, Minematsu K, Naritomi H, Tomoike H, Sawada J, Miyata T: Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res. 2008 Aug;31(8):1549-57. doi: 10.1291/hypres.31.1549. [PubMed:18971529 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11226258

By

Related Post

You Missed

Uncategorized

CaMKII-IN-1

Uncategorized

Lithocholic acid

Uncategorized

Gatifloxacin mesylate

Uncategorized

Irbesartan